TY - JOUR
T1 - Evaluation of the components of the insulin-like growth factors system in GH-deficient adults
T2 - Effects of twelve-month rhGH treatment
AU - Ferrante, E.
AU - Giavoli, C.
AU - Porretti, S.
AU - Vassallo, E.
AU - Ronchi, C. L.
AU - Lania, A. G.
AU - Beck-Peccoz, P.
AU - Spada, Anna
PY - 2006/5
Y1 - 2006/5
N2 - The impact of GH deficiency and rhGH replacement therapy on IGF-I, IGFBP-3 and ALS levels has been widely studied. There is less information available on IGF-II levels, the component of the ternary complex poorly dependent on GH. We investigate the components of IGFs system in 36 GHD adults (28M, 8F, age 45 ± 14 yrs) before and after 12 months of rhGH therapy (mean dose 0.3 ± 0.1 mg/day). One-hundred healthy sex- and age-matched subjects were studied for comparison. At baseline, GHD patients showed IGF-I and IGF-II levels and IGFs to IGFBP-3 molar ratios that were lower than controls. During therapy, IGF-I levels increased (p <0.01) to normal range. IGF-II levels, though higher than at baseline (p <0.01), remained lower than in controls (p <0.01). ALS and IGFBP-3 significantly increased (p <0.001). These modifications resulted in normalization in IGF-I to IGFBP-3 ratio, while no change in IGF-II to IGFBP-3 ratio was observed. In conclusion, the increase of serum IGF-II levels during rhGH treatment in GHD patients probably reflects the increase in the other components of ternary complex (ALS and IGFBP-3). However, serum IGF-II levels as well as IGF-II to IGFBP-3 ratio, although increased, were definitely lower than in controls. This last result, given the increasing evidences of a direct implication of IGF-II in cancer, may further confirm the safety of rhGH replacement in adults with severe GHD as diagnosed by appropriate stimulation tests.
AB - The impact of GH deficiency and rhGH replacement therapy on IGF-I, IGFBP-3 and ALS levels has been widely studied. There is less information available on IGF-II levels, the component of the ternary complex poorly dependent on GH. We investigate the components of IGFs system in 36 GHD adults (28M, 8F, age 45 ± 14 yrs) before and after 12 months of rhGH therapy (mean dose 0.3 ± 0.1 mg/day). One-hundred healthy sex- and age-matched subjects were studied for comparison. At baseline, GHD patients showed IGF-I and IGF-II levels and IGFs to IGFBP-3 molar ratios that were lower than controls. During therapy, IGF-I levels increased (p <0.01) to normal range. IGF-II levels, though higher than at baseline (p <0.01), remained lower than in controls (p <0.01). ALS and IGFBP-3 significantly increased (p <0.001). These modifications resulted in normalization in IGF-I to IGFBP-3 ratio, while no change in IGF-II to IGFBP-3 ratio was observed. In conclusion, the increase of serum IGF-II levels during rhGH treatment in GHD patients probably reflects the increase in the other components of ternary complex (ALS and IGFBP-3). However, serum IGF-II levels as well as IGF-II to IGFBP-3 ratio, although increased, were definitely lower than in controls. This last result, given the increasing evidences of a direct implication of IGF-II in cancer, may further confirm the safety of rhGH replacement in adults with severe GHD as diagnosed by appropriate stimulation tests.
KW - GH deficiency
KW - GH therapy
KW - IGFBPs
KW - IGFs
UR - http://www.scopus.com/inward/record.url?scp=33745005095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745005095&partnerID=8YFLogxK
U2 - 10.1055/s-2006-925402
DO - 10.1055/s-2006-925402
M3 - Article
C2 - 16718634
AN - SCOPUS:33745005095
VL - 38
SP - 352
EP - 355
JO - Hormone and Metabolic Research
JF - Hormone and Metabolic Research
SN - 0018-5043
IS - 5
ER -